Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 363

1.

[GIST: adjuvant treatment in Austria].

Brodowicz T, Kühr T.

Wien Med Wochenschr. 2009;159(15-16):399-402. doi: 10.1007/s10354-009-0687-3. Review. German.

PMID:
19696984
2.

Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.

Kang YK, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH.

Cancer Chemother Pharmacol. 2013 Jan;71(1):43-51. doi: 10.1007/s00280-012-1970-3. Epub 2012 Oct 7. Erratum in: Cancer Chemother Pharmacol. 2013 Feb;71(2):551-2.

PMID:
23053257
3.

[Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors].

Heger U, Weitz J, Lordick F.

Chirurg. 2008 Jul;79(7):630-7. doi: 10.1007/s00104-008-1526-6. Review. German.

PMID:
18548219
4.

[Gastrointestinal stromal tumors: recommendations for diagnosis, treatment and aftercare in Austria].

Ploner F, Zacherl J, Wrba F, Längle F, Bareck E, Eisterer W, Kühr T, Schima W, Häfner M, Brodowicz T; für das österreichische GIST-Panel.

Wien Med Wochenschr. 2009;159(15-16):370-82. doi: 10.1007/s10354-009-0685-5. Review. German.

PMID:
19696980
5.

Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.

Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W.

Med Sci Monit. 2007 Nov;13(11):CR515-522.

PMID:
17968300
6.

Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.

Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.

Anticancer Drugs. 2008 Jul;19(6):607-12. doi: 10.1097/CAD.0b013e32830138f9.

PMID:
18525320
7.

Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.

López RL, del Muro XG.

Anticancer Drugs. 2012 Jun;23 Suppl:S3-6. doi: 10.1097/CAD.0b013e3283559fab. Review.

PMID:
22739667
8.

[GIST refractory to imatinib treatment].

Onozawa Y, Terashima M.

Gan To Kagaku Ryoho. 2011 May;38(5):738-43. Japanese.

PMID:
21566433
9.

Imatinib: a review of its use in the management of gastrointestinal stromal tumours.

Siddiqui MA, Scott LJ.

Drugs. 2007;67(5):805-20. Review.

PMID:
17385949
10.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H.

J Clin Oncol. 2008 Feb 1;26(4):620-5. doi: 10.1200/JCO.2007.13.4403.

PMID:
18235121
11.

Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.

Gronchi A.

Eur J Cancer. 2013 Mar;49(4):884-92. doi: 10.1016/j.ejca.2012.10.025. Epub 2012 Dec 1. Review.

PMID:
23206668
12.
13.

Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).

Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Woźniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W.

J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97. Epub 2007 Apr 26.

PMID:
17458563
14.

c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.

Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E, Pilotti S.

Clin Cancer Res. 2007 Apr 15;13(8):2369-77.

15.

[A step foward in the treatment of GIST].

Fattoruso SI, Lopez M.

Clin Ter. 2008 Jul-Aug;159(4):223-4. Italian. No abstract available.

PMID:
18776977
16.

Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.

Utsunomiya T, Okamoto M, Yano S, Kameyama T, Matsuyama A, Kuma S, Yamamoto M, Fujiwara M, Ishida T.

Surg Today. 2008;38(1):65-7. Epub 2007 Dec 24.

PMID:
18085368
17.

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).

Nilsson B, Sjölund K, Kindblom LG, Meis-Kindblom JM, Bümming P, Nilsson O, Andersson J, Ahlman H.

Br J Cancer. 2007 Jun 4;96(11):1656-8. Epub 2007 May 29.

18.

Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials.

Eisenberg BL.

Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S24-9. Review.

PMID:
17101065
19.

GIST under imatinib therapy.

Sciot R, Debiec-Rychter M.

Semin Diagn Pathol. 2006 May;23(2):84-90. Review.

PMID:
17193821
20.

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).

Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, Kim KH, Yook JH, Kim BS, Kang YK.

J Surg Oncol. 2008 Jul 1;98(1):27-33. doi: 10.1002/jso.21065.

PMID:
18452195

Supplemental Content

Support Center